Physician profile
Eric M Jackson
NPI 1235131251
$1,479.70
in general payments reported to CMS, 2019-2025
18 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.27 · 2021: $240 · 2022: $480 · 2023: $376 · 2024: $185 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.98 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $249.64 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $208.33 | 2020-2023 | Fasenra, Tezspire |
| Merck Sharp & Dohme LLC | $135.79 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $82.18 | 2021-2023 | Freestyle Libre |
| Lilly USA, LLC | $71.77 | 2022-2024 | Zepbound, Jardiance |
| Exact Sciences Corporation | $63.11 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $58.07 | 2021-2024 | |
| Althera Pharmaceuticals LLC | $48.28 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $40.62 | 2023 | Gvoke Hypopen |
| Amgen INC. | $32.56 | 2024 | Otezla, Repatha |
| Sanofi Pasteur INC. | $31.00 | 2023 | |
| Abbvie INC. | $28.45 | 2021-2022 | |
| Mannkind Corporation | $26.66 | 2021 | |
| Arbor Pharmaceuticals, INC. | $23.71 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.49 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $14.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.